Patents Assigned to Bristol-Myers Squibb Company
-
Publication number: 20240238258Abstract: Disclosed are compounds of Formula (I) pharmaceutically acceptable salts thereof are defined herein, and pharmaceutical compositions thereof and combinations thereof, and methods of using the same as inhibitors of protein tyrosine phosphatases (PTPN2). These compounds are useful in treating cancer and diseases susceptible to PTPN2 inhibition.Type: ApplicationFiled: December 20, 2023Publication date: July 18, 2024Applicant: BRISTOL-MYERS SQUIBB COMPANYInventors: HAIBO LIU, YUCHENG MU, ANNAPURNA PENDRI, SHOSHANA L. POSY, JOANNE JEWETT BRONSON, LOUIS S. CHUPAK, LAURA AKULLIAN D'AGOSTINO
-
Publication number: 20240238416Abstract: This disclosure provides a method for treating glioma in a subject comprising administering to the subject an anti-Programmed Death-1 (PD-1) antibody. In some embodiments, this invention relates to methods for treating glioma in a subject comprising administering to the subject a combination of an anti-cancer agent which is an anti-Programmed Death-1 (PD-1) antibody and another anti-cancer agent such as an anti-Cytotoxic T-Lymphocyte Antigen-4 (CTLA-4) antibody.Type: ApplicationFiled: December 6, 2023Publication date: July 18, 2024Applicant: Bristol-Myers Squibb CompanyInventors: Vladimir CORIC, Shinta CHENG, I
-
Publication number: 20240239909Abstract: The disclosure provides for antibodies that bind CD40, including a humanized antibody. The antibodies bind CD40 and do not exhibit CD40 agonist activity. The antibodies may comprise a modified IgG1 Fc domain, and exhibit minimal activation of immature dendritic cells. Compositions comprising antibodies, methods of use for treatment of diseases involving CD40 activity, and use in the preparation of a medicament for treatment of a disease involving CD40 activity are provided.Type: ApplicationFiled: February 14, 2024Publication date: July 18, 2024Applicant: BRISTOL-MYERS SQUIBB COMPANYInventors: Aaron YAMNIUK, Mary STRUTHERS, Stanley R. KRYSTEK, JR., Akbar NAYEEM, Ginger RAKESTRAW
-
Publication number: 20240241129Abstract: The present disclosure relates to the finding that the ratio of circulating (i.e., peripheral blood) central memory T cells to circulating effector T cells in a cancer patient can predict whether a tumor has an inflammatory milieu or not. In addition, since having an inflammatory milieu (“hot tumor”) is a positive factor for responding to checkpoint inhibitors, e.g., PD-1 antagonists, this assay on peripheral blood can also be used to predict a response to a checkpoint inhibitor, e.g., an antibody or an antigen-binding portion thereof that specifically binds to a Programmed Death-1 (PD-1) receptor and inhibits PD-1 activity or an antibody or an antigen binding portion thereof that binds specifically to PD-1 ligand 1 (PD-L1) and inhibits PD-L1 activity.Type: ApplicationFiled: December 19, 2023Publication date: July 18, 2024Applicant: Bristol-Myers Squibb CompanyInventors: Nataly MANJARREZ ORDUÑO, Suzanne J. SUCHARD
-
Patent number: 12037324Abstract: The present invention provides compounds of Formula (I): wherein all variables are as defined in the specification, and compositions comprising any of such novel compounds. These compounds are biased agonists, or ?-Arrestin agonists of the angiotensin II receptor, which may be used as medicaments.Type: GrantFiled: July 11, 2022Date of Patent: July 16, 2024Assignees: Bristol-Myers Squibb Company, Université de MontréalInventors: Eldon Scott Priestley, Samuel Kaye Reznik, Edward H. Ruediger, James R. Gillard, Oz Scott Halpern, Wen Jiang, Jeremy Richter, Rejean Ruel, Sasmita Tripathy, Wu Yang, Xiaojun Zhang
-
Patent number: 12037323Abstract: The invention relates generally to compounds that are Mer-Ax1 inhibitors, pharmaceutical compositions containing said compounds and methods of treating proliferative disorders and disorders of dysregulated apoptosis, such as cancer, utilizing the compounds of the invention.Type: GrantFiled: May 2, 2019Date of Patent: July 16, 2024Assignee: Bristol-Myers Squibb CompanyInventors: Christine M. Tarby, Derek J. Norris, Julian C. Lo, Vijay T. Ahuja, Steven P. Seitz, Ashvinikumar V. Gavai, John S. Tokarski, Mohini Rajasagi, Michael Wichroski, Matthias Broekema
-
Publication number: 20240226821Abstract: The disclosure provides methods of in vitro dissolution of a solute, comprising agitating a solution placed in a vessel using a mobile paddle: wherein the solution comprises a solute, a media, and a plurality of beads; and wherein the paddle is submerged in the solution. In some aspects, the plurality of beads is positioned between the solute and the mobile paddle. In some aspects, the solute is sandwiched by the plurality of beads, wherein the solute is positioned both on top of and below the plurality of beads.Type: ApplicationFiled: May 5, 2022Publication date: July 11, 2024Applicant: Bristol-Myers Squibb CompanyInventors: Xujin LU, Lili LO
-
Publication number: 20240228664Abstract: The present application relates to particular anti-PAD4 (peptidyl arginine deiminase 4) antibodies, nucleic acids encoding the antibodies, vectors and host cells comprising the nucleic acids, and methods of making and using the antibodies.Type: ApplicationFiled: July 21, 2023Publication date: July 11, 2024Applicant: Bristol-Myers Squibb CompanyInventors: Lin Hui Su, Ekaterina Deyanova, Burce Ergel Gurbuzbalaban, Mariana Nacht, Samantha Elaine Pace, Yun Wang, Qing Xiao, Ramakrishna Chandran, Shailesh Dudhgaonkar, Michael Louis Doyle, Michael Gilman, Richard Huang, Akbar Nayeem, Alok Sharma, Qihong Zhao
-
Publication number: 20240228653Abstract: Methods of identifying and using PSGL-1 antagonists are provided. Such methods include, but are not limited to, methods of treating cancer. PSGL-1 antagonists include, but are not limited to, antibodies that bind PSGL-1 and antibodies that bind VISTA, wherein the antibodies inhibit PSGL-1 binding to VISTA, e.g., at acidic pH (e.g., pH 6.0), as well as PSGL-1 and VISTA extracellular domain polypeptides.Type: ApplicationFiled: December 18, 2023Publication date: July 11, 2024Applicants: Bristol-Myers Squibb Company, Five Prime Therapeutics, Inc.Inventors: Robert J. Johnston, Andrew Rankin, Arathi Krishnakumar, Paul O. Sheppard, Arvind Rajpal
-
Publication number: 20240228476Abstract: Disclosed are compounds of Formula (I) pharmaceutically acceptable salts thereof are defined herein, and pharmaceutical compositions thereof and combinations thereof, and methods of using the same as inhibitors of protein tyrosine phosphatases (PTPN2). These compounds are useful in treating cancer and diseases susceptible to PTPN2 inhibition.Type: ApplicationFiled: December 20, 2023Publication date: July 11, 2024Applicant: BRISTOL-MYERS SQUIBB COMPANYInventors: HAIBO LIU, YUCHENG MU, ANNAPURNA PENDRI, SHOSHANA L. POSY, JOANNE JEWETT BRONSON, LOUIS S. CHUPAK, LAURA AKULLIAN D'AGOSTINO
-
Patent number: 12030923Abstract: The invention provides for mammalian cells capable of producing recombinant CTLA4-Ig and variants thereof. The invention also provides for compositions comprising CTLA4-Ig and formulations thereof. The invention further provides for methods for mass-producing CTLA4-Ig from mammalian cells capable of producing this recombinant protein, and for purifying the CTLA4-Ig.Type: GrantFiled: November 25, 2020Date of Patent: July 9, 2024Assignee: Bristol-Myers Squibb CompanyInventors: Kirk J. Leister, Eugene J. Schaefer, Ronald Charles Bates, Elizabeth A. Bramhall, David Michael Didio, Robert Donaldson, Alan R. Flesher, Helen Gray Haggerty, David Henry Kirkley, John Malcolm Tabor, Lee K. Tay, Pallaiah Thammana, Ajoy Velayudhan, David Edward Smolin, Reb J. Russell, Thomas James Vanden Boom, Dean Woodrow Brownell, Jeffrey Schrimsher, Joyce Patricia Whitehead
-
Patent number: 12030878Abstract: Disclosed are compounds of Formula (I) (I) N-oxides, or salts thereof, wherein R1, G, A, R5, and n are defined herein. Also disclosed are methods of using such compounds as inhibitors of signaling through Toll-like receptor 7, or 8, or 9, and pharmaceutical compositions comprising such compounds. These compounds are useful in treating inflammatory and autoimmune diseases.Type: GrantFiled: December 14, 2018Date of Patent: July 9, 2024Assignee: Bristol-Myers Squibb CompanyInventors: Alaric J. Dyckman, Brian K. Whiteley, Dharmpal S. Dodd, Tasir Shamsul Haque
-
Patent number: 12030835Abstract: Disclosed are compounds of Formula (I) or a stereoisomer, a tautomer, or a pharmaceutically acceptable salt or solvate thereof, wherein Q is a 5-membered heterocyclyl or 5-membered heteroaryl having 1 to 4 heteroatoms independently selected from N, O, and S, substituted with zero to 4 R1; and A, X1, X2, X3, X4, Z1, Z2, R1, R2, R3a, R3b, a, b, and d are defined herein. Also disclosed are methods of using these compounds to modulate the activity of farnesoid X receptor (FXR); pharmaceutical compositions comprising these compounds; and methods of treating a disease, disorder, or condition associated with FXR dysregulation, such as pathological fibrosis, transplant rejection, cancer, osteoporosis, and inflammatory disorders, by using the compounds and pharmaceutical compositions.Type: GrantFiled: February 14, 2020Date of Patent: July 9, 2024Assignee: Bristol-Myers Squibb CompanyInventors: Dean A. Wacker, Susheel Jethanand Nara, Srinivas Cheruku, Kandhasamy Sarkunam, Firoz Ali Jaipuri, Soodamani Thangavel, Rishikesh Narayan, Subba Reddy Bandreddy, Srinivas Jogi, Pavan Kalyan Kathi
-
Publication number: 20240218022Abstract: This invention relates to novel anti-VISTA macrocyclic peptides and their related analogs with appended pharmacokinetic-enhancing tails (PKEs) with general structure of formula (I), which can be used as VISTA inhibitors.Type: ApplicationFiled: November 15, 2023Publication date: July 4, 2024Applicant: BRISTOL-MYERS SQUIBB COMPANYInventors: JENNIFER X. QIAO, YUNHUI ZHANG, KENNETH M. BOY, MICHAEL A. POSS
-
Patent number: 12023303Abstract: A combinatorial drug delivery device is provided herein including: a plurality of serially connectable modules, each including at least one drug component; and, a master controller. Each of the modules includes: a power line; a ground line; a multiplexer having a plurality of identified input channels, at least a subset of the input channels being selectively connected to one of the power and ground lines; a first digital logic line configured to select the input channels; a voltage reference line having a first resistor in line with an output of the multiplexer; a branch line connected to the voltage reference line having a normally closed switch thereon to connect the branch line to the ground line, the switch being opened with connection to a further module. The master controller selects, in sequence, the same identified input channels across all of the modules with measuring a reference voltage thereacross.Type: GrantFiled: November 2, 2020Date of Patent: July 2, 2024Assignee: BRISTOL-MYERS SQUIBB COMPANYInventors: Martin John McLoughlin, Stephen Lawrence Zieminski, Jeffrey Manfred Gunnarsson
-
Publication number: 20240208937Abstract: Disclosed herein are compounds and methods for the prevention and/or treatment of hemoglobinopathies. Also provided herein are such compounds for use in such methods. Also disclosed herein are pharmaceutical compositions comprising such compounds for use in such methods of preventing or treating hemoglobinopathies.Type: ApplicationFiled: November 3, 2023Publication date: June 27, 2024Applicant: Bristol-Myers Squibb CompanyInventors: Thomas J. Cummins, Daniel K. Cashion, Jacob T. Edwards, Antonia Lopez-Girona, Joshua Hansen, Scott Arne Johnson, Mark A. Nagy, Kevin M. Oberg, Hannah L. Powers, Giorgio Tamo
-
Publication number: 20240207238Abstract: Disclosed are compounds of Formula (I): pharmaceutically acceptable salts thereof are defined herein, and pharmaceutical compositions thereof and combinations thereof, and methods of using the same as inhibitors of protein tyrosine phosphatases (PTPN2). These compounds are useful in treating cancer and diseases susceptible to PTPN2 inhibition.Type: ApplicationFiled: November 8, 2023Publication date: June 27, 2024Applicant: BRISTOL-MYERS SQUIBB COMPANYInventors: ANNAPURNA PENDRI, HAIBO LIU, SHOSHANA L. POSY, YUCHENG MU, JOANNE JEWETT BRONSON, LAURA AKULLIAN D'AGOSTINO
-
Publication number: 20240209083Abstract: Provided herein are antibodies, or antigen-binding portions thereof, that bind to T-cell immunoglobulin and mucin-domain containing-3 (TIM3) protein. Also provided are uses of these antibodies, or antigen-binding portions thereof, in therapeutic applications, such as treatment of cancer. Further provided are cells that produce the antibodies, or antigen-binding portions thereof, polynucleotides encoding the heavy and/or light chain regions of the antibodies, or antigen-binding portions thereof, and vectors comprising the polynucleotides encoding the heavy and/or light chain regions of the antibodies, or antigen-binding portions thereof.Type: ApplicationFiled: October 5, 2023Publication date: June 27, 2024Applicant: Bristol-Myers Squibb CompanyInventors: Xiao Min SCHEBYE, Mark J. SELBY, Michelle Minhua HAN, Christine BEE, Andy X. DENG, Anan CHUNTHARAPAI, Brigitte DEVAUX, Huiming LI, Paul O. SHEPPARD, Alan J. KORMAN, Daniel F. ARDOUREL, Ekaterina DEYANOVA, Richard Y. HUANG, Guodong CHEN, Michelle KUHNE, Hong-An TRUONG
-
Patent number: 12018097Abstract: The disclosure is directed to the synthesis and improved methods for purifying macrocyclic peptides produced by solid phase peptide synthesis. The synthesized peptide is capped with an alkyne-functionalized or azide-functionalized compound of formula (I): prior to cleavage of the peptide from the solid phase support.Type: GrantFiled: September 13, 2022Date of Patent: June 25, 2024Assignee: Bristol-Myers Squibb CompanyInventors: Gardner S. Creech, Mahboubeh Kheirabadi, Martin D. Eastgate, David S. Nirschl, Percy H Carter
-
Patent number: 12016847Abstract: The present application relates generally to methods for treating prostate cancer with substituted tricyclic derivative is 2-[3-(1,4-dimethyl-1H-1,2,3-triazol-5-yl)-5-[(S)-(oxan-4-yl)(phenyl)methyl]-5H-pyrido[3,2-b]indol-7-yl]propan-2-ol as a bromodomain inhibitor, or the pharmaceutically acceptable salt thereof.Type: GrantFiled: March 7, 2022Date of Patent: June 25, 2024Assignee: Bristol-Myers Squibb CompanyInventors: Martina Malatesta, Ellen Hope Filvaroff